Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

By | December 7, 2021
Poolbeg Pharma, ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university’s knowledge transfer office.